Referring to a purine Derivative of formula (i), where L1 is nr8, o, S, S (or S) 2, (OR), among others r1 is H, alkyl - C20 haloalquilo C1, C1 - C20, among others x2 is n or CR5 R5 is H, halogen, C1 to C20 alkyl -, among others x1 is alquileno C1 - C20, o, C (or S), (OR), among others, D1 and D2 are aryl C6 C20 or h Eteroarilo with 1 to 6 heteroatom selected from o, N, S, F L2 is a Covalent Bond,Alquileno C1 - C20, among others R2 is nr6r7 R3 and R4 are alquenilo C20 alkyl C1, C2 and C20, =, CN, among others M is 1 or 2 n is an integer from 0 to 5 R6 and R7 are h, alkyl - C20 alquenilo C1, C2 - C20 haloalquilo, C1 - C20, among others R8 is H, alkyl - C20 haloalquilo C1, C1 - C20, among others. Preferred compounds are: (a), (b), among others. It also relates to a Pharmaceutical composition.These compounds modulate the activity of Toll like receptors (TLR) and are useful in the treatment of melanoma, Lung Cancer, COPD, Asthma, allergic rhinitis, among othersREFERIDA A UN DERIVADO DE PURINA DE FORMULA (I), DONDE L1 ES NR8, O, S, S(O)2, S(O), ENTRE OTROS R1 ES H, ALQUILO C1-C20, HALOALQUILO C1-C20, ENTRE OTROS X2 ES N O CR5 R5 ES H, HALOGENO, ALQUILO C1-C20, ENTRE OTROS X1 ES ALQUILENO C1-C20, O, C(O), S(O), ENTRE OTROS D1 Y D2 SON ARILO C6-C20 O HETEROARILO CON 1 A 6 HETEROATOMOS SELECCIONADOS DE O, N, S, F L2 ES UN ENLACE COVALENTE, ALQUILENO C1-C20, ENTRE OTROS R2 ES NR6R7 R3 Y R4 SON ALQUILO C1-C20, ALQUENILO C2-C20, =O, CN, ENTRE OTROS m ES 1 O 2 n ES UN ENTERO DE 0 A 5 R6 Y R7 SON H, ALQUILO C1-C20, ALQUENILO C2-C20, HALOALQUILO C1-C20, ENTRE OTROS R8 ES H, ALQUILO C1-C20, HALOALQUILO C1-C20, ENTRE OTROS. SON COMPUESTOS PREFERIDOS: (a), (b), ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA COMPOSICION FARMACEUTICA. DICHOS COMPUESTOS MODULAN LA ACTIVIDAD DE LOS RECEPTORES TIPO TOLL (TLR-7) Y SON UTILES EN EL TRATAMIENTO DE MELANOMA, CARCINOMA PULMONAR, ASMA, RINITIS ALERGICA, EPOC, ENTRE OTRAS
